| 肝素与低分子肝素治疗ST段抬高性心肌梗死有效性和安全性的Meta分析 |
| |
| 引用本文： | 李小华,孙毅毅.肝素与低分子肝素治疗ST段抬高性心肌梗死有效性和安全性的Meta分析[J].中国药房,2011(24):2272-2275. |
| |
| 作者姓名： | 李小华 孙毅毅 |
| |
| 作者单位： | 四川遂宁市第一人民医院;成都医学院; |
| |
| 摘 要： | 目的:采用循证医学的方法对肝素治疗ST段抬高性心肌梗死(STEMI)的有效性和安全性进行系统评价。方法:系统检索Cochrane图书馆、Medline、EMBase、CNKI、CBMdisc数据库,手工检索《中华心血管病杂志》等8种杂志,纳入有关肝素治疗STEMI的随机对照试验(RCT),并采用RevMan5.0软件进行数据分析。结果:最终纳入8个RCT,28179例患者。低分子肝素组与普通肝素组比较,病死率RR=0.92,95%CI(0.84,1.01),P=0.09]无统计学意义,但病死率/非致死性再梗死率RR=0.81,95%CI(0.76,0.88),P<0.00001]、再梗死率RR=0.66,95%CI(0.59,0.74),P<0.00001]低于普通肝素组,血运重建率RR=0.84,95%CI(0.73,0.97),P=0.02]、出血率RR=1.42,95%CI(1.21,1.68),P<0.0001]高于普通肝素组,差异有统计学意义。结论:肝素治疗STEMI的有效性和安全性评价中,低分子肝素显示了其优越性,但是出血率明显高于普通肝素组,因此可选用低分子肝素对STEMI患者进行抗凝治疗,但应注意出血引发的严重并发症的发生。
|
| 关 键 词： | 肝素 低分子肝素 急性心肌梗死 Meta分析 |
Meta-analysis of Effectiveness and Safety of Heparin and Low Molecular Heparin for ST-segment Elevation Myocardial Infarction |
| |
| LI Xiao-hua SUN Yi-yi.Meta-analysis of Effectiveness and Safety of Heparin and Low Molecular Heparin for ST-segment Elevation Myocardial Infarction[J].China Pharmacy,2011(24):2272-2275. |
| |
| Authors: | LI Xiao-hua SUN Yi-yi |
| |
| Affiliation: | LI Xiao-hua(Suining Municipal First People’s Hospital of Sichuan Province, Suining 629000, China) SUN Yi-yi(Chengdu Medical College, Chengdu 610083, China) |
| |
| Abstract: | OBJECTIVE: To evaluate the effectiveness and safety of heparin and low molecular heparin for ST-segment elevation myocardial infarction (STEMI) with evidence-based medicine. METHODS: Clinical controlled trials were retrieved from Cochrane Library, Medline, EMBase, CNKI, CBMdisc. We also searched 8 kinds of Chinese journals by hand, such as Chinese Journal of Cardiology. Randomized controlled trials (RCT) on heparin in the treatment of STEMI were included and analyzed by RevMan 5.0. RESULTS: 8 RCTs involovin... |
| |
| Keywords: | Heparin Low molecular heparin Myocardial infarction Meta-analysis |
| 本文献已被 CNKI 维普 等数据库收录！ |
|
